|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The 30-day incidence of major adverse cardiovascular events, the composite of cardiovascular death, nonfatal myocardial infarction, and ischemic stroke were significantly higher in AA homozygotes than in non-AA homozygotes (adjusted hazard ratio, 2.78; 95% CI, 1.13-6.82; P=0.026), irrespective of CYP2C19*2 loss-of-function polymorphism and known outcome predictors including age, sex, smoking, and diabetes mellitus.
|
31018667 |
2019 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The goal of this study is to determine the effect of the cytochrome P450 CYP2C19*2 polymorphism on the platelet response to clopidogrel in patients with and without diabetes mellitus (DM).
|
30073432 |
2018 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Body mass index (odds ratio [OR]=1.15; 95% CI: 1.03-1.27), diabetes mellitus (OR=3.46; 95% CI: 1.05-11.43), hematocrit (OR=0.75; 95% CI: 0.65-0.87), and <i>CYP2C19*2</i> (OR=4.44; 95% CI: 1.21-16.20) were the only independent predictors of HTPR.
|
29922082 |
2018 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data suggest that CYP2C19*17 ultra-rapid-metaboliser status is a protective factor against the development of diabetes during clozapine treatment, and increases the likelihood of improvement in schizophrenia.
|
28664816 |
2017 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients with an acute coronary event and a very poor, poor and normal CYP2C19 metabolizer genotype have a higher prevalence of diabetes mellitus needing insuline than patients with the rapid and ultrarapid metabolizers CPY2C19 genotype.
|
28473221 |
2017 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Genetic determinants (CYP2C19*2 polymorphism), advanced age, female gender, diabetes and reduced ventricular function are related to a higher risk to develop HcPR.
|
26520003 |
2016 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
To achieve on-treatment platelet reactivity similar to that seen with clopidogrel 75 mg in patients with neither DM nor CYP2C19*2, the following doses were required: 150 mg with only DM, 225 mg with only CYP2C19*2, and 300 mg with both DM and CYP2C19*2.
|
27009617 |
2016 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Paths from two clinical characteristics (diabetes mellitus and acute coronary syndrome (ACS)) and two genetic variants (CYP2C19*2 and CYP2C19*17) independently predicted HTPR (path coefficients: 0.11 0.10, 0.17, and -0.10, respectively; p<0.05 for all).
|
25051347 |
2014 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Patients were divided into two groups; DM (n=249), and non-DM (n=270), and clinical events were evaluated according to the carrier state, which included at least one CYP2C19 loss-of-function allele.
|
24821368 |
2014 |
|
Diabetes Mellitus
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Thus, results form this study seem to indicate no relationship between CYP2C9, CYP2C19, and CYP2D6 genotype and diabetes susceptibility in Bosnian population.
|
21108610 |
2010 |
|
Diabetes Mellitus
|
0.100 |
Biomarker
|
group |
BEFREE |
The classification and regression trees analysis demonstrated that CYP2C19*2 carrier status followed by diabetes mellitus was the best discriminator between a sufficient and an insufficient antiplatelet response to clopidogrel.
|
20510210 |
2010 |